Pharmacokinetic-Pharmacodynamic Simulation of Muscle Relaxation Antagonistic Conditions for Post-Operative...

Area of Science:

• Anesthesiology
• Pharmacology
• Clinical Trials

Background:

• Limited data on simulating rocuronium (Rb) effect-site concentrations (Ce_Rb) with real-time data during mechanical administration.
• Need to investigate post-operative recurarization and Ce_Rb changes post-sugammadex (SGX) with automated Rb dosing.

Purpose of the Study:

• To investigate post-operative recurarization and Ce_Rb dynamics following SGX administration.
• To evaluate the safety of automated Rb dosing and SGX reversal using PK-PD modeling.

Main Methods:

• Retrospective analysis of 74 patients from a clinical trial.
• Automated Rb administration to maintain TOF count (TOFC) of 1.
• Manual SGX administration with dose adjustments based on TOF ratio (TOFR) recovery (≥0.9).
• Analysis using a pharmacokinetic (PK)-pharmacodynamic (PD) simulation model.

Main Results:

• Average SGX dose: 2.2 ± 0.4 mg/kg; time to TOFR ≥0.9: 2.9 ± 1.1 min.
• Residual Ce_Rb at recovery (Ce_r): 0.3 ± 0.2 μg/mL.
• No instances of post-operative recurarization within 24 hours.
• PK-PD simulations showed transient Ce_Rb increases, but not beyond Ce_r, indicating no numerical recurarization risk.

Conclusions:

• Strict intraoperative TOFC maintenance and SGX administration until TOFR ≥0.9 prevent post-operative recurarization.
• Automated Rb dosing and targeted SGX reversal are effective and safe strategies.
• PK-PD modeling supports the absence of recurarization risk under these conditions.